HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: AJPH.2008.141846v1 99/6/1049    most recent Submit a response View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Wiessing, L. Articles by Griffiths, P. PubMed PubMed Citation Articles by Wiessing, L. Articles by Griffiths, P. Related Collections HIV/AIDS Drugs

Lucas Wiessing, MSc, Giedrius Likataviius, MD, Danica Klempová, MA, Dagmar Hedrich, MSc, Anthony Nardone, PhD and Paul Griffiths, MSc

At the time of the study, Lucas Wiessing, Danica Klempová, Dagmar Hedrich, and Paul Griffiths were with the European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal. Giedrius Likataviius and Anthony Nardone were with EuroHIV, Department of Infectious Diseases, Institut de Veille Sanitaire, St Maurice, France.

Correspondence: Correspondence should be sent to Lucas Wiessing, European Monitoring Centre for Drugs and Drug Addiction, Rua da Cruz de Santa Apolónia 23-25, 1149-045 Lisbon, Portugal (e-mail: Lucas.Wiessing{at}emcdda.europa.eu).

HIV-prevention measures specific to injection drug users (IDUs), such as opioid substitution treatment and needle-and-syringe programs, are not provided in many countries where injection drug use is endemic. We describe the incidence of diagnosed HIV infection in IDUs and the availability and coverage of opioid substitution and needle-and-syringe programs in the European Union and 5 middle- and high-income countries. Countries with greater provision of both prevention measures in 2000 to 2004 had lower incidence of diagnosed HIV infection in 2005 and 2006.